Biohm Technologies
Sam Schatz serves as the Chief Executive Officer at BIOHM Health, leading efforts to harness one of the world's largest microbiome datasets to develop innovative microbiome-based products for the dietary supplement market. In addition, Sam is the President of 92nd Street Y, collaborating with leadership to enhance programming for diverse communities nationwide, and serves as Chapter Communications Officer for YPO Polaris. As an investor and Managing Director of Corporate Development at AeroFarms, Sam focuses on local sustainable farming solutions. Advising for The Yield Lab and previously holding positions in private equity and asset management, Sam's educational background includes an MSc in Management and Finance from The London School of Economics and a BA in Political Science from Columbia University.
This person is not in any teams
Biohm Technologies
Biohm Technologies, based in Cleveland, OH, specializes in the development of targeted microbiome products leveraging the company’s extensive dataset of bacterial and fungal populations in the gut, a departure from the industry's predominant focus on bacteria alone. Biohm’s data-driven methodology, called Symbiont™, is the basis for the creation of award-winning ingredients validated through clinical trials. The company’s flagship ingredient is Mycohsa™, the first data-powered probiotic blend clinically shown to break down digestive biofilms and support optimal levels of both bacteria and yeasts for gut health. Biohm Technologies also offers its state-of-the-art, comprehensive microbiome gut testing kits as a private label solution for brands in the health and wellness space.